Document resource
Description In 2023, Respiratory Syncytial Virus (RSV) immunizations (Nirsevimab for infants and Abrysvo for pregnant mothers) were recommended by the Advisory Committee for Immunization Practices. To accelerate RSV protection across our health system, we implemented a multidisciplinary strategy with targeted interventions across different levels within the organization ( figure 1). In hospitals, we established administrative processes with electronic health record integration, negotiated increased payment for well newborn nurseries, enrolling facilities as Vaccines for Children sites and developed parent education materials. In primary care, we developed a network-wide strategy for both employed and independent practices, which included communication processes between hospitals and clinics to track RSV protection status, an incentive payment for office-based nirsevimab administration, and a direct-to-consumer digital and mass media campaign. Preliminary data for 2024–2025 season demonstrates a > 200% increase in RSV immunization uptake across the health system. Among our value-based care population, there were no intensive care unit (ICU) admissions and lower hospitalization rates in immunized infants. Additionally, the average length of stay for hospitalized infants decreased. To sustain our gains, we have launched quality improvement initiatives to adapt our strategies for next season.Abstract 30 Figure 1Nirsevimab immunization key driver diagram